{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:24:45Z","timestamp":1767839085998,"version":"3.49.0"},"reference-count":49,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,3,10]],"date-time":"2008-03-10T00:00:00Z","timestamp":1205107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Prolymphocytic leukaemias of B and T cell subtype are rare diseases. Despite recent advances in immunophenotyping and molecular cytogenetics,\u2003leading to a better understanding of the underlying cell biology of the\u2003prolymphocytic leukaemias, prognosis for these patients remains poor.\u2003Purine analogues and monoclonal antibodies have shown efficacy in B\u2010cell prolymphocytic leukaemia although further studies are warranted. Monoclonal antibody therapy with\u2003alemtuzumab has significantly improved outcome in T\u2010cell prolymphocytic leukaemia (T\u2010PLL) but responses\u2003are still transient and further disease progression is inevitable. While\u2003allogeneic stem cell transplant is an attractive option, due to the older age group of T\u2010PLL patients the morbidity and mortality associated with the procedure\u2003is significant.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2008.01069.x","type":"journal-article","created":{"date-parts":[[2008,3,11]],"date-time":"2008-03-11T01:28:47Z","timestamp":1205198927000},"page":"469-476","source":"Crossref","is-referenced-by-count":56,"title":["Prolymphocytic leukaemia of B\u2010 and T\u2010cell subtype: a state\u2010of\u2010the\u2010art paper"],"prefix":"10.1111","volume":"80","author":[{"given":"M.","family":"Dungarwalla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Matutes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. E.","family":"Dearden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,3,10]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1974.tb06769.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/9780470987056.ch38"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.42.6.567"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(03)00023-7"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401644"},{"key":"e_1_2_5_7_2","first-page":"1640","article-title":"The immunological profile of B\u2010cell disorders and proposal of a scoring system for the diagnosis of CLL","volume":"8","author":"Matutes E","year":"1994","journal-title":"Leukaemia"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(83)90084-5"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04913.x"},{"key":"e_1_2_5_10_2","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1182\/blood.V89.6.2015","article-title":"p53 abnormalities in B\u2010cell prolymphocytic leukaemia","volume":"89","author":"Lens D","year":"1997","journal-title":"Blood"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.9.3148.3148"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404238"},{"key":"e_1_2_5_13_2","first-page":"496","article-title":"Prolymphocytic leukemia: the therapeutic strategy","volume":"85","author":"Fava S","year":"1994","journal-title":"Recenti Prog Med"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199909093739"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)80164-H"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.8.658"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.37"},{"key":"e_1_2_5_18_2","first-page":"675a","article-title":"Fludarabine\/Cyclophosphamide chemotherapy for B\u2010prolymphocytic leukemia [abstract 2499]","volume":"102","author":"Herold M","year":"2003","journal-title":"Blood"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.d01-2061.x"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0805-z"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190400004521"},{"key":"e_1_2_5_22_2","first-page":"RA69","article-title":"Current treatment options in prolymphocytic leukemia","volume":"13","author":"Robak T","year":"2007","journal-title":"Med Sci Monit"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(200004)63:4<230::AID-AJH13>3.0.CO;2-2"},{"key":"e_1_2_5_24_2","volume-title":"Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissues. World Health Organisation Classification of Tumours 2001","author":"Jaffe ES","year":"2001"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(03)00132-X"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-003-3224-3"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2006.01.029"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/9780470987056.ch39"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(91)90228-M"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1097-1155"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.10.3920.3920_3920_3926"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-46870-4_9"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-4608(03)00104-3"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.26.12530"},{"key":"e_1_2_5_35_2","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood.V87.5.1923.1923","article-title":"Expression of p13MTCP1 is restricted to mature T\u2010cell proliferations with t(X;14) translocations","volume":"87","author":"Madani A","year":"1996","journal-title":"Blood"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0002"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(00)00039-3"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.12.3269.3269"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(97)00158-6"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-001-0381-z"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0925-5710(98)00074-7"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.1141"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000040035"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.12.2588"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.7.2667"},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1721"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.1.205"},{"key":"e_1_2_5_48_2","first-page":"2378","article-title":"Very high response rates in previously untreated T\u2010cell Prolymphocytic leukaemia patients receiving alemtuzumab (Campath\u20101H) therapy","volume":"102","author":"Dearden C","year":"2003","journal-title":"Blood"},{"key":"e_1_2_5_49_2","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1182\/blood.V106.11.2130.2130","article-title":"T\u2010PLL 1 protocol of the German CLL Study Group (GCLLSG)\u2010A prospective phase 2 trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FCM) followed by alemtuzumab consolidation as first line treatment in T\u2010PLL","volume":"106","author":"Hopfinger G","year":"2007","journal-title":"Blood"},{"key":"e_1_2_5_50_2","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1182\/blood.V106.11.1127.1127","article-title":"Clinical outcome of stem cell transplantation in patients with T cell prolymphocytic leukaemia previously treated with alemtuzumab : A multicentre experience","volume":"106","author":"Krishnan B","year":"2005","journal-title":"Blood"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2008.01069.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2008.01069.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T11:57:38Z","timestamp":1697371058000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2008.01069.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,10]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1111\/j.1600-0609.2008.01069.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2008.01069.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,10]]}}}